--- title: "Alzamend Neuro (ALZN) news: convertible notes" url: "https://aibio.space/companies/alzamend-neuro/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ALZN convertible notes news: Alzamend Neuro sells $7.5 million of Series D preferred to affiliate Ault Lending. Alzamend Neuro, Inc." --- ALZN Alzamend Neuro, Inc. NASDAQ · United States # Alzamend Neuro (ALZN) news ALZN convertible notes news Company Updates · 2026-09-29 ## [Alzamend Neuro presents lithium brain imaging results from phase 1/2a trial](https://aibio.space/news/alzamend-neuro-presents-lithium-brain-imaging-results-phase-1-2a-trial/) Slides filed with the SEC say the differences between AL001 and lithium carbonate were not statistically significant in the healthy cohort. ## Latest Alzamend Neuro news 1. 2026-08-03 Financings [Alzamend Neuro sells $7.5 million of Series D preferred to affiliate Ault Lending](https://aibio.space/news/alzamend-neuro-sells-7-5-million-series-d-preferred-affiliate-ault/) The agreement allows up to $25 million of Series D convertible preferred stock, and the first tranche closed July 31, 2026. 2. 2025-10-09 Financings [Alzamend Neuro issues 361,743 shares on conversion of Series B preferred stock](https://aibio.space/news/alzamend-neuro-issues-361-743-shares-conversion-series-b-preferred/) The shares were issued between October 1, 2025 and October 8, 2025. The company had 3,801,604 common shares outstanding as of October 8, 2025. 3. 2025-09-25 Financings [Alzamend Neuro issues 300,000 shares on conversion of Series B preferred stock](https://aibio.space/news/alzamend-neuro-issues-300-000-shares-conversion-series-b-preferred/) Between September 17 and September 25, 2025, 696 shares of Series B Convertible Preferred Stock converted into common stock. Alzamend had 3,439,861 common shares outstanding as of September 25, 2025. 4. 2025-08-01 Financings [Alzamend Neuro issues 243,429 shares on Series B preferred conversions](https://aibio.space/news/alzamend-neuro-issues-243-429-shares-series-b-preferred-conversions/) Alzamend Neuro (Nasdaq: ALZN) issued 243,429 common shares between July 23 and July 30, 2025 on conversion of Series B Convertible Preferred Stock. It had 3,139,861 common shares outstanding on July 30. ## Alzamend Neuro at a glance - **Ticker**: ALZN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jul 31, 2026**: $7.6 million ### Related companies - [Xilio Therapeutics](https://aibio.space/companies/xilio-therapeutics/) NASDAQ: XLO - [ARS Pharmaceuticals](https://aibio.space/companies/ars-pharmaceuticals/) NASDAQ: SPRY - [Viridian Therapeutics](https://aibio.space/companies/viridian-therapeutics/) NASDAQ: VRDN - [Ironwood Pharmaceuticals](https://aibio.space/companies/ironwood-pharmaceuticals/) NASDAQ: IRWD - [Neuphoria Therapeutics](https://aibio.space/companies/neuphoria-therapeutics/) NASDAQ: NEUP - [Pulmatrix](https://aibio.space/companies/pulmatrix/) NASDAQ: PULM - [Vaxxinity](https://aibio.space/companies/vaxxinity/) OTC: VAXX - [Aprea Therapeutics](https://aibio.space/companies/aprea-therapeutics/) NASDAQ: APRE ### Also on NASDAQ - [Beta Bionics](https://aibio.space/companies/beta-bionics/) BBNX - [SeaStar Medical Holding](https://aibio.space/companies/seastar-medical/) ICU - [Enlivex](https://aibio.space/companies/enlivex/) ENLV - [INTUITIVE SURGICAL INC](https://aibio.space/companies/intuitive-surgical/) ISRG - [Amarin Corporation](https://aibio.space/companies/amarin/) AMRN - [BioVie](https://aibio.space/companies/biovie/) BIVI ## What Alzamend Neuro does Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing novel products for Alzheimer's disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. Its pipeline has two drug candidates, both under royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation. The lead candidate, AL001, is an ionic cocrystal delivering lithium, salicylate and proline, and the company describes it as in clinical development in humans. A Phase IIA Multiple Ascending Dose trial was completed in March 2023, and the company says it identified a maximum tolerated dose. The company also reports a Lithium in Brain study in healthy subjects, with pharmacokinetics topline data reported in March 2026, and says a Phase II clinical trial of AL001 in patients with bipolar disorder was initiated in March 2026. A partnership with Massachusetts General Hospital and Harvard Medical School covers five Phase II imaging clinical trials. The second candidate, ALZN002, is a cell-based therapeutic vaccine intended to restore the immune system's ability to combat Alzheimer's. | Product or program | What it is | Stage | |---|---|---| | AL001 | Ionic cocrystal of lithium for Alzheimer's, bipolar disorder, depression and PTSD | in clinical development in humans; Phase II in bipolar disorder initiated March 2026 | | ALZN002 | Cell-based therapeutic vaccine intended to combat Alzheimer's | | Summarised from the company's [10-K filed Jul 22, 2026](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/az72426110k.htm). ## Alzamend Neuro annual financials | Line | FY ended Apr 30, 2026 | FY ended Apr 30, 2025 | |---|---|---| | Research and development | [$3.6 million](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/) | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/) | | Net income (loss) | [-$8.8 million](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/) | [-$4.5 million](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/) | | Cash from operations | [-$8.1 million](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/) | [-$6.6 million](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/) | | Cash and equivalents | [$710,689](https://www.sec.gov/Archives/edgar/data/1677077/000121465926011572/) | [$3.9 million](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/) | Latest balance sheet, Jul 31, 2026 (10-Q): cash and equivalents $7.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Alzamend Neuro Has Alzamend Neuro sold convertible notes? Our latest story on this, dated Aug 3, 2026: "Alzamend Neuro sells $7.5 million of Series D preferred to affiliate Ault Lending". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alzamend-neuro-sells-7-5-million-series-d-preferred-affiliate-ault/). What is the ticker symbol of Alzamend Neuro? Alzamend Neuro, Inc. trades under the ticker ALZN on NASDAQ. Where is Alzamend Neuro listed? Alzamend Neuro, Inc. is listed on NASDAQ. What is the SEC CIK of Alzamend Neuro? The SEC Central Index Key (CIK) for Alzamend Neuro, Inc. is 1677077. Its filings are on SEC EDGAR. How many shares does Alzamend Neuro have outstanding? 4,825,723 shares as of 2026-09-10, per the cover page of its 10-Q filed 2026-09-10. Which country or territory is Alzamend Neuro listed under? Our directory records Alzamend Neuro, Inc. under United States. What does Alzamend Neuro do? Our directory classifies Alzamend Neuro, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Alzamend Neuro? The ISIN recorded for Alzamend Neuro, Inc. is US02262M6057. Does aibio.space cover Alzamend Neuro? aibio.space lists Alzamend Neuro, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Alzamend Neuro incorporated? SEC records list its state or country of incorporation as DE. What does Alzamend Neuro develop? Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing novel products for Alzheimer's disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. Its pipeline has two drug candidates, both under royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation. What is AL001 from Alzamend Neuro? AL001: Ionic cocrystal of lithium for Alzheimer's, bipolar disorder, depression and PTSD Stage: in clinical development in humans; Phase II in bipolar disorder initiated March 2026. What is ALZN002 from Alzamend Neuro? ALZN002: Cell-based therapeutic vaccine intended to combat Alzheimer's Stage: not stated. Is Alzamend Neuro profitable? Alzamend Neuro, Inc. reported a net loss of $8.8 million for the fiscal year ended Apr 30, 2026, and used $8.1 million of cash in operations, per its annual report to the SEC. How much does Alzamend Neuro spend on research and development? $3.6 million in the fiscal year ended Apr 30, 2026, per its annual report. ## Investor discussion: Alzamend Neuro Members talk about Alzamend Neuro (ALZN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Alzamend Neuro, newest first. Each line links the filing it comes from. 1. 2026-08-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,3.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465926009469/az7312618k.htm) 2. 2026-04-17 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465926004806/p4172668k.htm) 3. 2026-03-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465926003620/g3202628k.htm) 4. 2026-02-26 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465926002583/i225262def14a.htm) 5. 2026-02-09 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465926001345/g29260pre14a.htm) 6. 2025-10-09 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465925014818/o1082528k.htm) 7. 2025-09-25 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465925014200/w9252538k.htm) 8. 2025-08-01 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465925011357/i812508k.htm) 9. 2025-05-08 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465925007204/ex99_1.htm) 10. 2025-04-25 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465925006405/i4252528k.htm) 11. 2025-03-13 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465925004335/z312254def14a.htm) 12. 2025-02-28 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465925003658/z2272508k.htm) 13. 2025-02-28 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1677077/000121465925003659/s227250pre14a.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ALZN on TradingView](https://www.tradingview.com/symbols/NASDAQ-ALZN/). ## SEC filings and registration - **SEC name**: Alzamend Neuro, Inc. - **CIK**: 1677077 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ALZN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: April 30 - **Filer category**:
Emerging growth company - **Business address**: 480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA, GA, 30326 - **Phone**: 844-722-6333 - **Shares outstanding**: 4,825,723 as of 2026-09-10 (10-Q filed 2026-09-10) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465926012132/x9282618k.htm) filed 2026-09-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1677077/000121465926011572/alz9226210q.htm) filed 2026-09-10 - [S-1](https://www.sec.gov/Archives/edgar/data/1677077/000121465926010726/p820265s1.htm) filed 2026-08-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465926009469/az7312618k.htm) filed 2026-08-03 - [10-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008832/az72426110k.htm) filed 2026-07-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465926008772/p7202618k.htm) filed 2026-07-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465926004806/p4172668k.htm) filed 2026-04-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465926003620/g3202628k.htm) filed 2026-03-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001677077), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Alzamend Neuro, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ALZN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Alzamend Neuro, Inc. - **Ticker**: ALZN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US02262M6057 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ALZN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/alzamend-neuro/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alzamend Neuro (ALZN) news: convertible notes", 2026-10-31, https://aibio.space/companies/alzamend-neuro/